恶性肿瘤术后复发和转移是影响患者长期生存的主要障碍，而常用麻醉药兼具促瘤和抗瘤效应。瑞马唑仑是新一代超短效苯二氮䓬类镇静药，在体外可通过多条信号通路直接抑制胶质瘤、肺癌、结直肠癌、胃癌、肝癌、前列腺癌细胞增殖和迁移，并诱导细胞凋亡，同时对围术期免疫功能具有一定的保护作用。总结了瑞马唑仑通过对细胞的直接作用、调节体内的免疫功能对恶性肿瘤影响的研究进展，以期拓展瑞马唑仑在肿瘤综合治疗中的应用。

Postoperative recurrence and metastasis of malignant tumors are major obstacles affecting long-term patient survival, while commonly used anesthetics exhibit both pro-tumor and anti-tumor effects. Remimazolam, a new-generation ultra-short-acting benzodiazepine sedative, can directly inhibit the cell proliferation and migration of glioma, lung cancer, colorectal cancer, gastric cancer, liver cancer, and prostate cancer cells through multiple signaling pathways in vitro, while also inducing cell apoptosis. Additionally, it provides certain protective effects on perioperative immune function. This article summarizes the research progress on the impact of remimazolam on malignant tumors through its direct effects on cells and its modulation of immune function, aiming to expand the application of remimazolam in comprehensive tumor therapy.

R965

吴阶平医学基金会课题（320.6750.2024-05-44）